HLNCF OTC
Credit Risk of going bust: lower than 82% of companies Debt: 19.6% of company value Bonds: none of note held by US funds details ▾
Total debt $10.95B against a stock market value of $44.86B.
Distance to default 10.07 (Merton model): prices to 2026-10-26, balance sheet 2025-12-31, debt counted $6.70B (short-term plus half of long-term), stock volatility 23.4%; Altman Z'' 3.98. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Weybridge, SU KT13 0NY
GB
Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Its business activities cover extensive regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers various solutions such as oral hygiene products, pain management remedies, respiratory care items, digestive health aids, and a selection of vitamins, minerals, and supplements. Its notable brand collection features Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially named DRVW 2022 plc before officially rebranding to Haleon plc in February 2022. Its main office is situated in Brentford, United Kingdom.
